| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
|
S3 |
p.
|
artikel
|
| 2 |
Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy?
|
Zambelli, Alberto
|
|
|
|
S3 |
p.
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
|
S3 |
p.
|
artikel
|
| 4 |
ELCC
|
|
|
|
|
S3 |
p.
|
artikel
|
| 5 |
ESMO
|
|
|
|
|
S3 |
p.
|
artikel
|
| 6 |
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
|
de Azambuja, Evandro
|
|
|
|
S3 |
p.
|
artikel
|
| 7 |
ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer
|
Vecchione, Loredana
|
|
|
|
S3 |
p.
|
artikel
|
| 8 |
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies
|
Colombo, Ilaria
|
|
|
|
S3 |
p.
|
artikel
|
| 9 |
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer
|
Passaro, Antonio
|
|
|
|
S3 |
p.
|
artikel
|
| 10 |
ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
|
Catanese, Silvia
|
|
|
|
S3 |
p.
|
artikel
|
| 11 |
ESMO Open special series on new emerging targets in cancer immunotherapy
|
Lambertini, Matteo
|
|
|
|
S3 |
p.
|
artikel
|
| 12 |
ESTRO
|
|
|
|
|
S3 |
p.
|
artikel
|
| 13 |
ESTS
|
|
|
|
|
S3 |
p.
|
artikel
|
| 14 |
ETOP
|
|
|
|
|
S3 |
p.
|
artikel
|
| 15 |
IASLC
|
|
|
|
|
S3 |
p.
|
artikel
|
| 16 |
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma
|
Aeppli, Stefanie
|
|
|
|
S3 |
p.
|
artikel
|
| 17 |
LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study
|
Awad, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 18 |
LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2
|
Bradley, J.D.
|
|
|
|
S3 |
p.
|
artikel
|
| 19 |
2MO Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON
|
Felip, E.
|
|
|
|
S3 |
p.
|
artikel
|
| 20 |
3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2
|
Gentzler, R.D.
|
|
|
|
S3 |
p.
|
artikel
|
| 21 |
196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)
|
Cheng, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 22 |
1MO A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation
|
Lu, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 23 |
177MO Cardiovascular assessment in lung cancer screening: Initial findings from the European 4-IN-THE-LUNG-RUN trial
|
Han, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 24 |
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study
|
García Campelo, M.R.
|
|
|
|
S3 |
p.
|
artikel
|
| 25 |
197MO Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group
|
Mountzios, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 26 |
176MO Low-dose computed tomography lung cancer screening participants live longer than matched controls: A population-based study
|
Dziedzic, R.
|
|
|
|
S3 |
p.
|
artikel
|
| 27 |
137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)
|
Zhang, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 28 |
194MO Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): Efficacy and safety results
|
Zhang, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 29 |
244MO Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC
|
Cappuzzo, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 30 |
6MO Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study
|
Leighl, N.
|
|
|
|
S3 |
p.
|
artikel
|
| 31 |
195MO Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity
|
Hummel, H-D.
|
|
|
|
S3 |
p.
|
artikel
|
| 32 |
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
|
Lambertini, Matteo
|
|
|
|
S3 |
p.
|
artikel
|
| 33 |
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
|
Etxeberria, Iñaki
|
|
|
|
S3 |
p.
|
artikel
|
| 34 |
New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)
|
Starzer, Angelika M.
|
|
|
|
S3 |
p.
|
artikel
|
| 35 |
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
|
Piechutta, Manuel
|
|
|
|
S3 |
p.
|
artikel
|
| 36 |
New emerging targets in cancer immunotherapy: the role of GITR
|
Buzzatti, Giulia
|
|
|
|
S3 |
p.
|
artikel
|
| 37 |
New emerging targets in cancer immunotherapy: the role of neoantigens
|
De Mattos-Arruda, Leticia
|
|
|
|
S3 |
p.
|
artikel
|
| 38 |
New emerging targets in cancer immunotherapy: the role of TIM3
|
Friedlaender, Alex
|
|
|
|
S3 |
p.
|
artikel
|
| 39 |
New emerging targets in cancer immunotherapy: the role of VISTA
|
Tagliamento, Marco
|
|
|
|
S3 |
p.
|
artikel
|
| 40 |
Notice and Disclosure
|
|
|
|
|
S3 |
p.
|
artikel
|
| 41 |
4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes
|
Valdiviezo, N.
|
|
|
|
S3 |
p.
|
artikel
|
| 42 |
193O Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: A brief report from the CONVERT trial
|
Walls, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 43 |
108O Surgical outcomes from RATIONALE-315: Randomized, double-blind, phase III study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC
|
Yue, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 44 |
45P Actionable mutations in matched liquid and tissue biopsy next-generation sequencing
|
Ko, E.Y-L.
|
|
|
|
S3 |
p.
|
artikel
|
| 45 |
198P Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial
|
Cheng, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 46 |
126P Adjuvant aumolertinib for resected EGFR-mutated stage IA2-IIIA non-small cell lung cancer: Updated results from a multiple-center real-world experience
|
Zhang, Q.
|
|
|
|
S3 |
p.
|
artikel
|
| 47 |
220P Advancing lung adenocarcinoma treatment: Establishing KRAS-driven organoids for drug screening
|
Tas, I.
|
|
|
|
S3 |
p.
|
artikel
|
| 48 |
184P A framework to support implementation of low-dose computed tomography (LDCT) lung cancer screening: Research methodology and opportunities for impact
|
Wilcox, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 49 |
245P Age-adjusted trends of pulmonary large cell neuroendocrine carcinoma
|
Aly, A.S.E.S.
|
|
|
|
S3 |
p.
|
artikel
|
| 50 |
72P A high-polyphenol dietary intervention to improve response to immune checkpoint blockade for lung cancer via modification of the microbiome
|
Spakowicz, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 51 |
142P AI-based approaches to predict early response in unresectable LA-NSCLC patients undergoing chemoradiation
|
Greco, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 52 |
8P Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: Secondary analyses of patient-relevant endpoints from MARIPOSA-2
|
Tomasini, P.
|
|
|
|
S3 |
p.
|
artikel
|
| 53 |
249P Analysis of clinical and prognostic characteristics of patients with lung cancer and solid organ transplantation
|
Cutillas, M. Martinez
|
|
|
|
S3 |
p.
|
artikel
|
| 54 |
87P An artificial neural network system to predict the response to sintilimab based on the RNA data of ORIENT-3 study
|
Xie, T.
|
|
|
|
S3 |
p.
|
artikel
|
| 55 |
116P A novel lung nodule localization method: Predicting the watershed boundary of target blood vessels with AI simulated dyeing model
|
Chen, Z.
|
|
|
|
S3 |
p.
|
artikel
|
| 56 |
92P A novel R-code approach for efficient irAE identification from medical records of NSCLC patients treated with ICIs
|
Waissengrin, B.
|
|
|
|
S3 |
p.
|
artikel
|
| 57 |
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer
|
Le, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 58 |
71P A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NCT03991819)
|
Theriau, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 59 |
113P A propensity-based analysis of SBRT and VATS for early-stage lung cancer: A guide to data-driven support and decision-making in a multidisciplinary tumour board
|
van Kerkhove, O.
|
|
|
|
S3 |
p.
|
artikel
|
| 60 |
109P A revised international association for the study of lung cancer grading system in invasive pulmonary adenocarcinoma: The inclusion of invasive mucinous adenocarcinomas
|
Li, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 61 |
86P Artificial intelligence tools to predict early progression of non-small cell lung cancer patients treated with immunotherapy: Preliminary evidence from a single-centre experience of black-box and white-box models pairing
|
Ogliari, F.R.
|
|
|
|
S3 |
p.
|
artikel
|
| 62 |
12P Atezolizumab plus bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance: Final results from the randomised, non-comparative phase II ETOP ABC-lung trial
|
Frueh, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 63 |
115P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-grade patterns
|
Chen, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 64 |
124P Automated measurement of coronary artery calcifications predicts survival in resected stage I lung cancer
|
Pastorino, U.
|
|
|
|
S3 |
p.
|
artikel
|
| 65 |
235P Baseline values of circulating nucleosomes in non-small lung cancer (NSCLC): ONCOPRO_LUNG study
|
Couraud, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 66 |
69P Biomarker-driven TAM RTK inhibitor plus immunotherapy would benefit NSCLC in first-line setting: Implications from phase III ORIENT-11 trial
|
Li, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 67 |
231P Cancer-associated fibroblast-expressed nicotinamide N-methyltransferase is negatively associated with metastasis of lung adenocarcinomas
|
Wang, P.
|
|
|
|
S3 |
p.
|
artikel
|
| 68 |
150P Cardioimaging in stage III lung cancer patients undergoing chemoRT: Preliminary CARERT results
|
Gagliardi, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 69 |
224P Cerebrospinal fluid-based mutation abundance index (MAI) correlated to clinical outcome in leptomeningeal metastasis of non-small cell lung cancer with EGFR mutations
|
Zhu, W.
|
|
|
|
S3 |
p.
|
artikel
|
| 70 |
170P Change in the epidemiology and costs of metastatic lung cancer in France between 2013 and 2021: Observational study using the SNDS
|
de Pouvourville, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 71 |
252P Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project
|
Serrano, A.V. Ospina
|
|
|
|
S3 |
p.
|
artikel
|
| 72 |
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study
|
Scattolin, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 73 |
120P Circulating exosomal biomarkers as a predictive and prognostic marker in non-metastatic-treated NSCLC
|
Bulut, E.
|
|
|
|
S3 |
p.
|
artikel
|
| 74 |
234P Clinical findings and genomic characterization of NRG-1 alterations with a comprehensive genome profiling (CGP) in advanced non-small cell lung cancer (ANSCLC)
|
Vita, E.
|
|
|
|
S3 |
p.
|
artikel
|
| 75 |
23P Clinical impact and prognostic value of EGFR mutation co-occurring with ALK, ROS1, RET fusions, or MET exon 14 skipping mutations in Chinese patients with non-small cell lung cancer
|
Shen, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 76 |
202P Clinical outcomes to second-line treatment, after failing chemoimmunotherapy, in ES-SCLC
|
Andreas, V.J.
|
|
|
|
S3 |
p.
|
artikel
|
| 77 |
229P Clinicopathologic and genomic features of patients with mucinous lung adenocarcinoma and response to systemic therapies
|
Di Federico, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 78 |
230P Clinicopathologic and molecular features of STK11-mutated NSCLC
|
Saw, P.L.S.
|
|
|
|
S3 |
p.
|
artikel
|
| 79 |
27P CNS-progression patterns in patients with EGFR-mutant NSCLC receiving standard platinum-based chemotherapy post-osimertinib
|
Attili, I.
|
|
|
|
S3 |
p.
|
artikel
|
| 80 |
213P Comprehensive genomic atlas of small cell lung cancer finds PKD1L1 mutation associated with poor prognosis and drug susceptibility
|
Wang, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 81 |
14P Consolidative stereotactic radiotherapy in metastatic EGFR-mutant non-small cell lung cancer receiving first-line third-generation EGFR tyrosine kinase inhibitors: A prospective, multicenter, phase II trial
|
Zhou, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 82 |
167P Copy number intratumour heterogeneity in the context of metastatic seeding
|
Makker, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 83 |
73P Correlation between diet, microbiome composition and clinical outcomes in patients with non-small cell lung cancer
|
Malo, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 84 |
212P Correlation of 68Ga-SSO120 PET with SSTR2 expression and prognostic value in patients with small cell lung cancer
|
Mavroeidi, I.
|
|
|
|
S3 |
p.
|
artikel
|
| 85 |
185P Cost and impact assessment of AI-enhanced image analysis in lung cancer screening
|
Lancaster, H.L.
|
|
|
|
S3 |
p.
|
artikel
|
| 86 |
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy
|
Kotecha, R.
|
|
|
|
S3 |
p.
|
artikel
|
| 87 |
59P Datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Nonsquamous (NSQ) histology in the phase III TROPION-Lung01 trial
|
Girard, N.
|
|
|
|
S3 |
p.
|
artikel
|
| 88 |
163P Decoding the tumor immune microenvironment to unleash effective immunotherapy avenues for epithelioid malignant pleural mesothelioma
|
Haymaker, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 89 |
246P Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis
|
Van der Sar, I.G.
|
|
|
|
S3 |
p.
|
artikel
|
| 90 |
241P Development and characterization of a novel DLL3-targeting antibody drug conjugate (ADC) for the treatment of solid tumors
|
Lin, L.N.
|
|
|
|
S3 |
p.
|
artikel
|
| 91 |
42P Development of an online tool for the management of drug-drug interactions with the ROS1/TRK tyrosine kinase inhibitor repotrectinib
|
Burger, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 92 |
133P Development of CT image-based atelectasis simulation and non-invasive lung nodule localization system
|
Hwang, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 93 |
55P Differences in response to immune treatment between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
|
Pinto, L. Masfarre
|
|
|
|
S3 |
p.
|
artikel
|
| 94 |
253P Digital decision support for structural improvement of lung cancer tumor boards: Using standard cases to optimize workflow
|
Gross-Ophoff-Mueller, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 95 |
218P DSG2+ cancer stem cells co-located with POSTN+ myofibroblasts in the tumor boundary that determines the efficacy of immunotherapy in non-small cell lung cancer
|
Fan, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 96 |
65P Durvalumab combined with chemotherapy and radiotherapy in patients with oligometastatic non-small cell lung cancer (SABRcure)
|
Li, Q.
|
|
|
|
S3 |
p.
|
artikel
|
| 97 |
157P Durvalumab impacts progression-free survival but not local control in patients with inoperable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
|
Zehentmayr, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 98 |
143P Efficacy and safety of aumolertinib (AUM) with radiotherapy versus concurrent chemoradiotherapy (cCRT) in the treatment of unresectable stage III EGFR-mutant NSCLC: A multicenter, randomized, open-label phase III study (ADVANCE)
|
Bi, N.
|
|
|
|
S3 |
p.
|
artikel
|
| 99 |
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs
|
Hou, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 100 |
32P Efficacy and safety of furmonertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: A real-world retrospective study
|
Han, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 101 |
205P Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small cell lung cancer
|
Shi, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 102 |
139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis
|
Han, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 103 |
201P Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: An international multicentric analysis
|
Gomez-Randulfe Rodriguez, M.I.
|
|
|
|
S3 |
p.
|
artikel
|
| 104 |
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression
|
Blasi, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 105 |
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression
|
Markovic, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 106 |
159P Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB–IIIB lung squamous cell carcinoma
|
Liu, J.C.
|
|
|
|
S3 |
p.
|
artikel
|
| 107 |
114P Efficacy of perioperative/neoadjuvant immunotherapy combined with chemotherapy: Pooled analysis of specific subgroups in randomized controlled trials
|
Ergün, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 108 |
24P EGFR PACC mutations occur more frequently in compound than classical mutations with improved responses to TKIs
|
Le, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 109 |
132P Enhanced lung nodule malignancy prediction through clinical integration in a deep-learning radiomic model
|
Rosell, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 110 |
111P Enhancing negative predictive value of landmark undetectable molecular residual disease with baseline cell free DNA features based XGBoost model in resected non-small cell lung cancer
|
Zhang, J-T.
|
|
|
|
S3 |
p.
|
artikel
|
| 111 |
122P Evaluating the predictive accuracy of the Lee Revised Cardiac Risk Index for postoperative complications and survival after robotic-assisted pulmonary lobectomy
|
Antill, B.
|
|
|
|
S3 |
p.
|
artikel
|
| 112 |
39P Evaluation of body mass composition (BMC) changes in metastatic ALK-positive non-small cell lung cancer (ALK-mNSCLC) patients treated with anti-ALK tyrosine kinase inhibitors (aALK-TKIs): Preliminary results
|
Grisanti, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 113 |
153P Evaluation of chemoradiotherapy-induced radiation pneumonia in non-small cell lung cancer patients with a history of the human coronavirus disease 2019 (COVID-19)
|
Nabizade, U.
|
|
|
|
S3 |
p.
|
artikel
|
| 114 |
22P Evaluation of co-mutation in EGFR-mutant non-small cell lung cancer by next generation sequencing (NGS): Retrospective cohort study in South Korea
|
Kim, J.Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 115 |
182P Evolution of lung cancer mortality in Spain: 1980-2022, a joinpoint analysis
|
Ruano-Ravina, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 116 |
51P Exploring the prognostic value of TP53 mutation in NSCLC in the era of precision oncology: A prospective real-world study
|
Chiu, M.K.L.
|
|
|
|
S3 |
p.
|
artikel
|
| 117 |
187P Exposure to asbestos slate roofing in households and risk of lung cancer: Case-control study
|
Baez-Saldana, R.
|
|
|
|
S3 |
p.
|
artikel
|
| 118 |
138P Faecalibacterium prausnitzii enhances tumor response to perioperative nivolumab and chemotherapy
|
Rodriguez-Festa, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 119 |
131P FDG PET-CT as an imaging biomarker in predicting the molecular profile of treatment-naïve NSCLC
|
Palsapure, A.A.
|
|
|
|
S3 |
p.
|
artikel
|
| 120 |
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer
|
Werner-Wasik, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 121 |
240P Feasibility of detecting NSCLC-associated fusion genes in long-term preserved FFPE samples
|
Lin, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 122 |
35P Final data from phase I/II LIBRETTO-001 trial of selpercatinib in RET fusion-positive non-small cell lung cancer
|
Gautschi, O.
|
|
|
|
S3 |
p.
|
artikel
|
| 123 |
61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study
|
Zhou, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 124 |
62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial
|
Zhou, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 125 |
9P First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)
|
Lee, C.K.
|
|
|
|
S3 |
p.
|
artikel
|
| 126 |
154P Five-year survival and safety outcomes from the START-NEW-ERA non-randomised phase II trial
|
Arcidiacono, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 127 |
74P Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study
|
Yang, J-J.
|
|
|
|
S3 |
p.
|
artikel
|
| 128 |
243P FOXP4 promotes lung cancer cell proliferation and invasion by regulating tumor-associated macrophage polarization through the β-catenin/FOSL2/ARID5A signaling pathway
|
Yan, Q.
|
|
|
|
S3 |
p.
|
artikel
|
| 129 |
15P Furmonertinib combined with anlotinib as the first-line treatment in patients with EGFR exon 21 Leu858Arg mutation: Results from FOCUS-A study
|
Han, B.
|
|
|
|
S3 |
p.
|
artikel
|
| 130 |
169P Genomic landscape of NSCLC brain metastases and its potential association with TP53 and tumor mutation burden: A territory-wide program in Hong Kong
|
Kam, T.Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 131 |
20P Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients post osimertinib first line treatment failure: An interim analysis of GPS study
|
Shi, Y-K.
|
|
|
|
S3 |
p.
|
artikel
|
| 132 |
237P Genomic profiling of aggressive pathologic features in lung adenocarcinoma
|
Lin, Y-D.
|
|
|
|
S3 |
p.
|
artikel
|
| 133 |
178P Germline testing in non-small cell lung cancer (NSCLC): Real-world impact of the discovery of germline pathogenic variants (PGV) in the INHERITY LC (ILC) study
|
Montes, J.C. Laguna
|
|
|
|
S3 |
p.
|
artikel
|
| 134 |
78P Healthcare costs and survival in the era of immunotherapy for stage IV non-small cell lung cancer
|
Vrinzen, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 135 |
121P Health-related quality of life (HRQoL) outcomes from CheckMate 77T: Neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC
|
Spicer, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 136 |
179P Immunoprecipitation of tumor-associated ctDNA fragments for novel lung cancer liquid biopsy
|
Micallef, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 137 |
166P Impact of immunotherapy (IT) on overall survival (OS) of patients with malignant pleural mesothelioma (MPM) adjusted for tumor histology
|
Perez, S.M. Cedres
|
|
|
|
S3 |
p.
|
artikel
|
| 138 |
191P Impact of perifissural nodules on lung cancer screening with AI as the initial reader
|
Han, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 139 |
186P Impact of poverty and depopulation on the survival of patients with metastatic non-small cell lung cancer
|
Posado-Domínguez, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 140 |
183P Improving timeliness of diagnosis of lung cancer patients through implementation of a web-based lung cancer referral pathway
|
Otty, Z.
|
|
|
|
S3 |
p.
|
artikel
|
| 141 |
96P Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens
|
Vendittelli, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 142 |
83P Integrating proteomic gene signature-based machine learning model predicts PD-1 monotherapy response in non-small cell lung cancer
|
Zhang, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 143 |
141P Integrative radiomic analysis of peri-tumoral and habitat zones for predicting major pathological response to neoadjuvant immunotherapy and chemotherapy in non-small cell lung cancer: A multicenter, retrospective, cohort study
|
Huang, W.
|
|
|
|
S3 |
p.
|
artikel
|
| 144 |
161P Intensity-modulated radiotherapy (IMRT)-adapted chemoradiotherapy (CRT) followed by durvalumab (Durva) for locally advanced non-small cell lung cancer (NSCLC): 2-year update from a multicenter prospective observational study (WJOG12019L)
|
Hata, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 145 |
236P INTENT study: Assessment of fast track (FT) panel with IHC, RT-PCR and FISH as an alternative or rescue to NGS panel testing failure in NSCLC
|
De Marchi, P.R.
|
|
|
|
S3 |
p.
|
artikel
|
| 146 |
146P Inter-fraction variation of internal target volume of lung tumour with 4D CT and 4D kV CBCT
|
Raja, K.
|
|
|
|
S3 |
p.
|
artikel
|
| 147 |
174P Intracranial (IC) activity of ivonescimab (ivo) alone or in combination with platinum doublet chemotherapy (PC) in patients (Pts) with advanced non-small cell lung cancer (aNSCLC) and brain metastases (BMs)
|
Zhang, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 148 |
145P I-SAbR in unresectable LA-NSCLC patients receiving durvalumab in START-NEW-ERA non-randomised phase II trial
|
Anselmo, P.
|
|
|
|
S3 |
p.
|
artikel
|
| 149 |
67P Lesion-based results of the non-small cell lung cancer (NSCLC) subgroup in the ARTIC trial: Abscopal effects in metastasized cancer patients treated with radiotherapy and immune checkpoint inhibition
|
Käsmann, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 150 |
219P Leveraging gut metagenomic k-mer signature for the development of a practical and robust model to predict immunotherapy response in NSCLC
|
Zhang, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 151 |
80P LILRB2+ defines a monocyte subset which identifies responders of PD-1/PD-L1 immunotherapy with or without chemotherapy in NSCLC
|
Luo, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 152 |
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)
|
Leonetti, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 153 |
206P Liver kinase B1 expression is associated with improved overall survival and decreased CD8+ tumor infiltrating lymphocytes in small cell lung cancer
|
Maso, A. Dal
|
|
|
|
S3 |
p.
|
artikel
|
| 154 |
88P Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
|
Schlintl, V.
|
|
|
|
S3 |
p.
|
artikel
|
| 155 |
82P Longitudinal proteomics and single-cell transcriptomics reveal HDAC3 as an immunotherapy biomarker in advanced non-small cell lung cancer
|
Dai, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 156 |
28P Long-term survival and treatment (tx) patterns in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced NSCLC treated with first-line (1L) osimertinib (osi): German cohort of a global real-world (rw) observational study
|
Griesinger, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 157 |
40P Lorlatinib-associated weight gain and dyslipidaemia: A single centre UK experience
|
John, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 158 |
189P Lung cancer in young adults, age < 45 years: Clinical characteristics, treatment, histological and molecular features
|
Fremand, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 159 |
207P Lurbinectedin induces multimodal immune activation and augments the anti-tumor immune response in small cell lung cancer
|
Sen, T.
|
|
|
|
S3 |
p.
|
artikel
|
| 160 |
204P Maintenance of anti-tumour innate immune response in SCLC with DNA-PK inhibition
|
de Rosa, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 161 |
53P MET exon 14 skipping mutations in non-small cell lung cancer: Real-world data from the Italian biomarker ATLAS database
|
Reale, M.L.
|
|
|
|
S3 |
p.
|
artikel
|
| 162 |
58P Molecular characteristics and prognostic value of homologous recombination deficiency (HRD) in non-small cell lung cancer patients
|
Wang, Z.
|
|
|
|
S3 |
p.
|
artikel
|
| 163 |
76P Monitoring pembrolizumab response in patients with metastatic non-small cell lung cancer using circulating tumour DNA and circulating tumour cells
|
Kakouri, A.C.
|
|
|
|
S3 |
p.
|
artikel
|
| 164 |
238P Mutational patterns in lung cancer: Insights from a nationwide database in Israel
|
Turgeman, I.
|
|
|
|
S3 |
p.
|
artikel
|
| 165 |
222P Mutational variant allele frequency profile as a biomarker of response to immune checkpoint inhibitors in non-small cell lung cancer
|
Gao, R.
|
|
|
|
S3 |
p.
|
artikel
|
| 166 |
31P Myelosuppression risk from epidermal growth factor receptor-tyrosine kinase inhibitors, carboplatin chemotherapy, or both in EGFR mutated non-small cell lung cancer (NSCLC)
|
Girard, N.
|
|
|
|
S3 |
p.
|
artikel
|
| 167 |
151P Myocardial strain evaluation with cardiovascular MRI in patients with locally-advanced NSCLC treated with chemotherapy and radiation therapy
|
Pardo de Santayana, M. García
|
|
|
|
S3 |
p.
|
artikel
|
| 168 |
148P Neoadjuvant EGFR-TKI combined with chemotherapy improves the complete response rate in operable EGFR-mutant NSCLC patients: A multicenter real-world study
|
Yan, W.
|
|
|
|
S3 |
p.
|
artikel
|
| 169 |
158P Neoadjuvant treatment in stage III NSCLC: Comparison with NADIM 2 trial as a gold standard
|
Casas, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 170 |
140P New inflammatory biomarkers in uresectable stage III NSCLC treated with radio-chemotherapy (RCT) followed by durvalumab: Preliminary results of the Neutrality trial
|
Olmetto, E.
|
|
|
|
S3 |
p.
|
artikel
|
| 171 |
47P Next-generation sequencing using tissue specimen collected with a 1.1 mm-diameter cryoprobe in patients with lung cancer
|
Eom, J.S.
|
|
|
|
S3 |
p.
|
artikel
|
| 172 |
21P NGS and FISH for MET amplification detection in post EGFR-TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multi-center study in China
|
Zheng, Q.
|
|
|
|
S3 |
p.
|
artikel
|
| 173 |
181P Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands
|
van Doorn-Wink, K.
|
|
|
|
S3 |
p.
|
artikel
|
| 174 |
188P North American college students experience gap in online access to vaping cessation resources
|
Gunturi, A.S.
|
|
|
|
S3 |
p.
|
artikel
|
| 175 |
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors
|
Cognigni, V.
|
|
|
|
S3 |
p.
|
artikel
|
| 176 |
91P Observational retro-prospective study on immune checkpoint inhibitors (ICIs) treatment duration in patients with advanced non-small cell lung cancer (aNSCLC) (I-STOP study)
|
Gemelli, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 177 |
155P Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14
|
Almeida, S. Cardoso
|
|
|
|
S3 |
p.
|
artikel
|
| 178 |
7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC
|
Paz-Ares, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 179 |
64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1
|
Baramidze, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 180 |
11P Patritumab deruxtecan (HER3-DXd) in previously treated patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC: Updated safety results from HERTHENA-Lung01
|
Hayashi, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 181 |
75P PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase II umbrella trial (CTONG 1702)
|
Liu, S-Y.M.
|
|
|
|
S3 |
p.
|
artikel
|
| 182 |
160P Perioperative and patient reported outcomes of robotic-assisted and video-assisted thoracoscopic surgery for patients with NSCLC receiving neoadjuvant immunotherapy: A real-world cohort study
|
Wu, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 183 |
49P Perioperative circulating tumor DNA redefines induced oligometastatic non-small cell lung cancer at the molecular level
|
Fu, R.
|
|
|
|
S3 |
p.
|
artikel
|
| 184 |
70P Phase II clinical study of envafolimab combined with recombinant human endostatin and chemotherapy as a first-line treatment for driver gene-negative advanced non-small cell lung cancer
|
Yuan, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 185 |
68P Phase II results of ivonescimab (ivo) a novel PD-1/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced/metastatic squamous (Sq) non-small cell lung cancer (NSCLC)
|
Zhang, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 186 |
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)
|
Wolf, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 187 |
149P POSITION: Characterising risk factors and outcomes in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC) who fail to complete concurrent chemoradiotherapy (cCRT) or progress during or shortly after cCRT
|
Mountzios, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 188 |
233P Predictive value of immunohistochemistry assessment of mutated p53 for response and survival outcomes in patients with lung squamous cell cancer following neoadjuvant immunochemotherapy
|
Huang, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 189 |
89P Predictors of real-world (rw) outcomes in patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) treated with pembrolizumab-based maintenance (MT)
|
Velcheti, V.
|
|
|
|
S3 |
p.
|
artikel
|
| 190 |
134P Predictors of success and complications in electromagnetic navigation bronchoscopy of peripheral lung lesions: A retrospective cohort study
|
Lang, D.
|
|
|
|
S3 |
p.
|
artikel
|
| 191 |
125P Preliminary analysis on safety of the DEDALUS phase II trial: Induction chemo-durvalumab followed by reduced-dose radiotherapy and maintenance durvalumab for patients with unresectable stage III NSCLC
|
Filippi, A.R.
|
|
|
|
S3 |
p.
|
artikel
|
| 192 |
144P Preliminary safety and efficacy of iruplinalkib after chemoradiotherapy (CRT) in ALK/ROS1+ unresectable non-small cell lung cancer (NSCLC): Part 1 results from the INNOVATION study
|
Wang, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 193 |
56P Prevalence, clinical characteristics, and treatment outcomes of patients with KRAS-mutated non-squamous NSCLC and PD-L1 expression: Real-life data analysis
|
Pankovics, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 194 |
190P Prevalence of germline variants in Indian non-small cell lung cancer patients with family history of cancer
|
Rastogi, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 195 |
18P Preventing CNS metastasis in EGFR-mutant NSCLC patients without baseline CNS metastasis using aumolertinib
|
Cun, F. Shen
|
|
|
|
S3 |
p.
|
artikel
|
| 196 |
77P Prognostic and predictive value of soluble PD-1 and PD-L1 in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
|
Syrigos, N.
|
|
|
|
S3 |
p.
|
artikel
|
| 197 |
26P Prognostic factors and outcomes of patients (Pts) with advanced NSCLC while on osimertinib (Osi) treatment (Tx): A retrospective database study
|
Pérol, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 198 |
242P Prognostic role of tumor microenvironment features in advanced non-small cell lung cancer molecular subtypes: A multicentric, retrospective study
|
Zullo, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 199 |
210P Prophylactic cranial irradiation (PCI) in patients with limited-stage small cell lung cancer (LS-SCLC) in the era of magnetic resonance imaging surveillance: A systematic review and meta-analysis
|
Käsmann, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 200 |
44P Protecting supernatant cfRNA from cytology samples for the detection of fusions in advanced non-small cell lung cancer (NSCLC) patients
|
Wang, Z.
|
|
|
|
S3 |
p.
|
artikel
|
| 201 |
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study
|
Wong, C.H.L.
|
|
|
|
S3 |
p.
|
artikel
|
| 202 |
50P Radiomic features of both primary lung nodules and lymph node metastases on chest CT associated with progression-free survival in advanced non-small cell lung cancer patients
|
Khorrami, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 203 |
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)
|
Khorrami, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 204 |
37P ReAlec interim analysis: An observational study to evaluate the real-world clinical management and outcomes of patients (pts) with advanced ALK+ NSCLC treated with alectinib
|
Bria, E.
|
|
|
|
S3 |
p.
|
artikel
|
| 205 |
93P Real-world analysis of first-line maintenance (1LM) immunotherapy (IO) ± pemetrexed for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
|
Minchom, A.R.
|
|
|
|
S3 |
p.
|
artikel
|
| 206 |
48P Real-world clinical utility of next-generation sequencing ctDNA for patients with advanced lung squamous cell carcinoma
|
García Pardo de Santayana, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 207 |
172P Real-world data of anolotinib for lung cancers with liver metastases in China
|
Zhuo, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 208 |
33P Real-world data of furmonertinib for patients with advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
|
Liu, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 209 |
247P Real-world evidence of immune checkpoint inhibitor treatment in lung cancer patients from a Belgian multicenter study
|
Geldhof, V.
|
|
|
|
S3 |
p.
|
artikel
|
| 210 |
79P Real-world overall survival after planned alternative dosing for pembrolizumab in the treatment of NSCLC: A nationwide retrospective non-inferiority analysis
|
Grit, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 211 |
90P Real-world (RW) post-progression outcomes and treatment (tx) patterns after first-line (1L) immuno-oncology (IO) regimens in patients (pts) with metastatic (m) NSCLC: CORRELATE
|
Liu, S.V.
|
|
|
|
S3 |
p.
|
artikel
|
| 212 |
29P Real-world safety of osimertinib in Chinese patients with non-small cell lung cancer (NSCLC)
|
Han, B.
|
|
|
|
S3 |
p.
|
artikel
|
| 213 |
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) from ALTA-1L
|
Delmonte, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 214 |
25P Real-world treatment patterns and outcomes in the US after first-line (1L) osimertinib (osi) in patients with epidermal growth factor receptor (EGFR)-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
|
Griesinger, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 215 |
217P Redox-high lung adenocarcinoma driven by KEAP1/STK11/SMARCA4 mutation shapes immune-desert tumor microenvironment and attenuates the efficacy of immunotherapy
|
Wei, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 216 |
19P Resistance mechanism to first-line osimertinib in EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) in China: Preliminary data from FLOURISH study
|
Zhou, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 217 |
57P Retrospective comparative analysis of KRAS mutations in mNSCLC patients treated with first-line immunotherapy or chemoimmunotherapy
|
Rossi, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 218 |
118P Role of PD-L1 and pathological complete response (pCR) with neoadjuvant (NEO) or perioperative (PERIOP) immune-checkpoint inhibitors (ICI) and platinum-based chemotherapy (PCT) in resectable non-small cell lung cancer (NSCLC): A systematic review and metanalysis
|
Nuccio, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 219 |
60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study
|
Cappuzzo, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 220 |
10P Safety and tolerability of first-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFRm advanced NSCLC: Data from FLAURA2
|
Lee, C.K.
|
|
|
|
S3 |
p.
|
artikel
|
| 221 |
36P Selpercatinib treatment beyond progression (PD) in RET fusion-positive NSCLC: Association with pattern of PD
|
De Miguel Luken, M.J.
|
|
|
|
S3 |
p.
|
artikel
|
| 222 |
227P Sexual dimorphism in immune profile of early and advanced NSCLC
|
Mazzaschi, G.
|
|
|
|
S3 |
p.
|
artikel
|
| 223 |
251P Sexual dysfunction in patients with lung cancer: Interim analysis of the LUDICAS study
|
Serrano, A.V. Ospina
|
|
|
|
S3 |
p.
|
artikel
|
| 224 |
135P Simultaneous noninvasive imaging of LAG-3 and PD-L1 for noninvasive immunotyping in lung cancers
|
Zhao, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 225 |
81P Single-cell and bulk RNA sequencing analysis of the pan-cancer immune microenvironment identifies a novel tumor-associated macrophage signature predicting immunotherapy response
|
Zhou, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 226 |
221P Single-cell transcriptomics reveals CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small cell lung cancer
|
Wen, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 227 |
209P Small cell lung cancer in never smokers: A descriptive analysis
|
Ruano-Ravina, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 228 |
228P SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGFβ signaling
|
Quintanal-Villalonga, Á.
|
|
|
|
S3 |
p.
|
artikel
|
| 229 |
180P Substantial radiologist workload reduction can be achieved if artificial intelligence is used as a first-read filter at baseline in lung cancer screening
|
Lancaster, H.L.
|
|
|
|
S3 |
p.
|
artikel
|
| 230 |
173P Surgery versus stereotactic body radiation therapy as initial treatment for pulmonary oligometastases from colorectal cancer: A propensity score analysis
|
Wang, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 231 |
171P Systematic review-based treatment algorithm for multidisciplinary treatment of lung cancer bone metastases
|
Rim, C.H.
|
|
|
|
S3 |
p.
|
artikel
|
| 232 |
250P Taurolidine as an adjunct in the management of pleural effusion and air leakage after pulmonary resection: A randomized controlled trial
|
Byun, C-S.
|
|
|
|
S3 |
p.
|
artikel
|
| 233 |
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC
|
Marzano, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 234 |
46P The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study
|
Yildirim, M.E.
|
|
|
|
S3 |
p.
|
artikel
|
| 235 |
156P The impact of the COVID-19 pandemic on the treatment patterns of patients with stage III unresectable non-small cell lung cancer
|
Borghetti, P.
|
|
|
|
S3 |
p.
|
artikel
|
| 236 |
41P The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI treated NSCLC patients
|
Zwierenga, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 237 |
239P The new IASLC grading system for invasive lung adenocarcinoma predicts the prognosis of patients receiving neoadjuvant immunotherapy
|
Xu, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 238 |
226P The PerMediNA initiative: A pilot precision oncology project on lung cancer in North Africa
|
Hamdi, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 239 |
225P The potential synergistic mechanism of the combination of osimertinib and furmonertinib (3+3 mode): Evidence from an in vitro experimental study and structural modeling
|
Liang, W.
|
|
|
|
S3 |
p.
|
artikel
|
| 240 |
84P The predictive and prognostic value of tumor infiltrating lymphocytes in advanced non-small cell lung cancer
|
Eissa, M.M.
|
|
|
|
S3 |
p.
|
artikel
|
| 241 |
119P The role and mechanism of estrogen receptor beta based on SRSF2 in gender differences of lung adenocarcinoma immunotherapy with anti-PD-1
|
Tang, H.
|
|
|
|
S3 |
p.
|
artikel
|
| 242 |
110P The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma
|
Liu, C.
|
|
|
|
S3 |
p.
|
artikel
|
| 243 |
13P Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous non-small cell lung cancer (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy
|
Han, B.
|
|
|
|
S3 |
p.
|
artikel
|
| 244 |
165P Tissue genomic profiling of pleural mesothelioma patients treated with immunotherapy: Unraveling genetic alterations and complexity
|
Ambrosini, P.
|
|
|
|
S3 |
p.
|
artikel
|
| 245 |
211P Transcriptional and epigenetic landscape of neuroendocrine transformation during emergence of resistance to targeted therapies in EGFR mutant lung adenocarcinoma
|
Sen, T.
|
|
|
|
S3 |
p.
|
artikel
|
| 246 |
63P Treatment-free survival (TFS) in patients (pts) with mNSCLC treated with 1L nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in CheckMate (CM) 9LA
|
Reck, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 247 |
112P Treatment landscape for stages I–III NSCLC in the United States (US) community setting before and after 2020
|
Donington, J.S.
|
|
|
|
S3 |
p.
|
artikel
|
| 248 |
203P Treatment patterns and real-world outcomes of extensive-stage small cell lung cancer: A retrospective, multicenter study
|
Cani, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 249 |
152P Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): Interim analysis of a global real-world (RW) study
|
Neal, J.
|
|
|
|
S3 |
p.
|
artikel
|
| 250 |
232P Tumor spread through air spaces is an independent predictor of recurrence-free survival in patients with resected pulmonary lymphoepithelial carcinoma
|
Chen, P-H.
|
|
|
|
S3 |
p.
|
artikel
|
| 251 |
117P Tumour spread through air spaces is a determiner for treatment of clinical stage I non-small cell lung cancer: Thoracoscopic segmentectomy vs lobectomy
|
Petersen, R.H.
|
|
|
|
S3 |
p.
|
artikel
|
| 252 |
30P Uncommon EGFR kinase domain mutations and responses to EGFR inhibitors: A systematic review
|
Borgeaud, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 253 |
95P Understanding the real-world (RW) impact of time between treatment regimens on clinical outcomes in patients with metastatic NSCLC previously treated with immunotherapy (IO) in the US community oncology setting
|
Spira, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 254 |
34P Updated data from Beamion LUNG-1, a phase (ph) Ia/b trial of the HER2-specific tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631), in patients (pts) with HER2 mutation-positive (m+) NSCLC
|
Wu, Y-L.
|
|
|
|
S3 |
p.
|
artikel
|
| 255 |
43P Updated efficacy and circulating tumour (ct)DNA analysis in patients (pts) with TRK fusion lung cancer treated with larotrectinib (laro)
|
Drilon, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 256 |
123P Updated safety of perioperative durvalumab for resectable NSCLC in AEGEAN
|
Urban, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 257 |
168P Validation of lung specific and lung molecular graded prognostic assessment score in metastatic NSCLC with brain metastases from India
|
Tibdewal, A.R.
|
|
|
|
S3 |
p.
|
artikel
|
| 258 |
127P Waning effect of adjuvant EGFR TKIs in resected EGFR-mutated (EGFR-m) NSCLC: A systematic review and meta-analysis of randomized clinical trials (RCTs)
|
Imbimbo, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 259 |
130P Whole-body PET imaging to study bone metabolism in pre- and post-treatment lung cancer patients
|
Ronghe, R.
|
|
|
|
S3 |
p.
|
artikel
|
| 260 |
Table of Contents
|
|
|
|
|
S3 |
p.
|
artikel
|
| 261 |
136TiP A cohort study on the diagnosis of benign or malignant lung nodules based on synapse 3D software AI devascularization technique
|
Guo, Q.
|
|
|
|
S3 |
p.
|
artikel
|
| 262 |
105TiP Adebrelimab combined with famitinib in the treatment of PD-L1≥50% advanced non-small cell lung cancer with brain metastases: A prospective, single-arm trial (BRAIN-AF01)
|
Xu, W.
|
|
|
|
S3 |
p.
|
artikel
|
| 263 |
162TiP An update on the VIGILANCE study: Developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer
|
Horne, A.
|
|
|
|
S3 |
p.
|
artikel
|
| 264 |
254TiP A phase I clinical trial testing the dose escalation and expansion of pressurized intrathoracic hyperthermic aerosol cisplatin administration (PITHAC) for the management of pleural carcinosis
|
Perentes, J.Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 265 |
102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2
|
Wu, Y-L.
|
|
|
|
S3 |
p.
|
artikel
|
| 266 |
216TiP A phase II study of consolidation serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer (ASTRUM-LC01)
|
Wu, Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 267 |
215TiP A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemo-radiotherapy (CRT): DURVALUNG trial
|
Gobbini, E.
|
|
|
|
S3 |
p.
|
artikel
|
| 268 |
128TiP A phase II, two parallel group study of neoadjuvant and adjuvant targeted treatment in NSCLC with BRAF V600 or MET exon 14 mutations
|
Zhao, S.
|
|
|
|
S3 |
p.
|
artikel
|
| 269 |
99TiP A randomized phase II study of lazertinib alone versus lazertinib plus bevacizumab for advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking history
|
Ahn, B.C.
|
|
|
|
S3 |
p.
|
artikel
|
| 270 |
255TiP [DREAM] Double lung transplant registry aimed for lung-limited malignancies: A prospective registry study for medically refractory cancers
|
Chung, L.I-Y.
|
|
|
|
S3 |
p.
|
artikel
|
| 271 |
107TiP Dry powder inhaled cisplatin in stage IV NSCLC: The phase I/IIa CIS-DPI-01 study
|
Brandão, M.
|
|
|
|
S3 |
p.
|
artikel
|
| 272 |
104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies
|
Paz-Ares, L.
|
|
|
|
S3 |
p.
|
artikel
|
| 273 |
100TiP Phase II study of aumolertinib combined with local radiation therapy for EGFR mutated stage IV NSCLC patients with oligometastasis
|
Zhao, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 274 |
106TiP PULSE, a non-inferiority study of maintenance pembrolizumab at usual or low dose in non-squamous lung cancer
|
Masip, J. Remon
|
|
|
|
S3 |
p.
|
artikel
|
| 275 |
98TiP Safety and efficacy of aumolertinib combined with anlotinib as 1st-line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation
|
Jiang, Z.
|
|
|
|
S3 |
p.
|
artikel
|
| 276 |
103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)
|
Barlesi, F.
|
|
|
|
S3 |
p.
|
artikel
|
| 277 |
214TiP Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774)
|
Hummel, H-D.
|
|
|
|
S3 |
p.
|
artikel
|
| 278 |
101TiP The efficacy and safety of furmonertinib in advanced NSCLC patients with EGFR mutations and CNS metastases based on ctDNA detection in peripheral blood and CSF (FAITH)
|
Li, X.
|
|
|
|
S3 |
p.
|
artikel
|
| 279 |
Title Page
|
|
|
|
|
S3 |
p.
|
artikel
|
Tijdschrift beschrijving